Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Correction to: Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA.

Schmidkonz C, Krumbholz M, Atzinger A, Cordes M, Goetz TI, Prante O, Ritt P, Schaefer C, Agaimy A, Hartmann W, Rössig C, Fröhlich B, Bäuerle T, Dirksen U, Kuwert T, Metzler M.

Eur J Nucl Med Mol Imaging. 2020 Feb 13. doi: 10.1007/s00259-019-04672-2. [Epub ahead of print]

PMID:
32052098
2.

Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines.

Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, Sandalcioglu IE, Neyazi B, Moritz T, Meyer J, Rossig C, Altvater B, Eiz-Vesper B, Morgan MA, Abken H, Schambach A.

Cancers (Basel). 2020 Feb 6;12(2). pii: E375. doi: 10.3390/cancers12020375.

3.

"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.

Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel JC, Jäger D, Wels WS, Bachmann M.

Sci Rep. 2020 Feb 7;10(1):2141. doi: 10.1038/s41598-020-59082-4.

4.

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.

Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G.

Eur J Cancer. 2020 Mar;127:52-66. doi: 10.1016/j.ejca.2019.12.029. Epub 2020 Jan 24.

5.

Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Scheer M, Blank B, Bauer S, Vokuhl C, Stegmaier S, Feuchtgruber S, Henssen A, Sparber-Sauer M, Eggert A, Handgretinger R, Pekrun A, Rossig C, Rutkowski S, Schlegel PG, Schrappe M, Simon T, Kazanowska B, Niggli F, Ladenstein R, Ljungman G, Jahnukainen K, Fuchs J, Bielack SS, Koscielniak E, Klingebiel T; Cooperative Weichteilsarkom Studiengruppe [CWS].

J Cancer Res Clin Oncol. 2020 Apr;146(4):953-960. doi: 10.1007/s00432-019-03121-9. Epub 2020 Jan 13.

PMID:
31932909
6.

Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients.

Kelley LM, Schlegel M, Hecker-Nolting S, Kevric M, Haller B, Rössig C, Reichardt P, Kager L, Kühne T, Gosheger G, Windhager R, Specht K, Rechl H, Tunn PU, Baumhoer D, Wirth T, Werner M, von Kalle T, Nathrath M, Burdach S, Bielack S, von Lüttichau I.

J Clin Oncol. 2020 Mar 10;38(8):823-833. doi: 10.1200/JCO.19.00827. Epub 2020 Jan 13.

PMID:
31928458
7.

Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review.

Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A.

BMC Cancer. 2020 Jan 6;20(1):16. doi: 10.1186/s12885-019-6492-5.

8.

Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.

Isfort I, Elges S, Cyra M, Berthold R, Renner M, Mechtersheimer G, Åman P, Larsson O, Ratner N, Hafner S, Simmet T, Schliemann C, Rossig C, Dirksen U, Grünewald I, Wardelmann E, Huss S, Hartmann W, Trautmann M.

Sci Rep. 2019 Dec 23;9(1):19704. doi: 10.1038/s41598-019-56247-8.

9.

Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA.

Schmidkonz C, Krumbholz M, Atzinger A, Cordes M, Goetz TI, Prante O, Ritt P, Schaefer C, Agaimy A, Hartmann W, Rössig C, Fröhlich B, Bäuerle T, Dirksen U, Kuwert T, Metzler M.

Eur J Nucl Med Mol Imaging. 2019 Dec 18. doi: 10.1007/s00259-019-04649-1. [Epub ahead of print] Erratum in: Eur J Nucl Med Mol Imaging. 2020 Feb 13;:.

PMID:
31853559
10.

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

van Tilburg CM, Milde T, Witt R, Ecker J, Hielscher T, Seitz A, Schenk JP, Buhl JL, Riehl D, Frühwald MC, Pekrun A, Rossig C, Wieland R, Flotho C, Kordes U, Gruhn B, Simon T, Linderkamp C, Sahm F, Taylor L, Freitag A, Burhenne J, Foerster KI, Meid AD, Pfister SM, Karapanagiotou-Schenkel I, Witt O.

Clin Epigenetics. 2019 Dec 10;11(1):188. doi: 10.1186/s13148-019-0775-1.

11.

Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.

Steinestel K, Trautmann M, Jansen EP, Dirksen U, Rehkämper J, Mikesch JH, Gerke JS, Orth MF, Sannino G, Arteaga MF, Rossig C, Wardelmann E, Grünewald TGP, Hartmann W.

Mol Oncol. 2020 Feb;14(2):248-260. doi: 10.1002/1878-0261.12610. Epub 2019 Dec 21.

12.

Redirecting T cells to treat solid pediatric cancers.

Rauwolf KK, Rossig C.

Cancer Metastasis Rev. 2019 Dec;38(4):611-624. doi: 10.1007/s10555-019-09821-5. Review.

PMID:
31811551
13.

Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation.

Linke C, Ehlert K, Ahlmann M, Fröhlich B, Mohring D, Burkhardt B, Rössig C, Groll AH.

Mycoses. 2020 Feb;63(2):172-180. doi: 10.1111/myc.13029. Epub 2019 Nov 24.

PMID:
31661569
14.

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, Grunewald L, Zirngibl F, Flemmig C, Jensen MC, Rossig C, Joussen A, Henssen A, Eggert A, Schulte JH, Künkele A.

BMC Cancer. 2019 Sep 9;19(1):895. doi: 10.1186/s12885-019-6131-1.

15.

Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.

Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, Burdach S, Classen CF, Claviez A, Debatin KM, Ebinger M, Eggert A, Faber J, Flotho C, Frühwald M, Graf N, Jorch N, Kontny U, Kramm C, Kulozik A, Kühr J, Sykora KW, Metzler M, Müller HL, Nathrath M, Nüßlein T, Paulussen M, Pekrun A, Reinhardt D, Reinhard H, Rössig C, Sauerbrey A, Schlegel PG, Schneider DT, Scheurlen W, Schweigerer L, Simon T, Suttorp M, Vorwerk P, Schmitz R, Kluge R, Mauz-Körholz C, Körholz D, Gattenlöhner S, Bräuninger A.

Leukemia. 2020 Jan;34(1):151-166. doi: 10.1038/s41375-019-0541-6. Epub 2019 Aug 20.

PMID:
31431735
16.

Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center.

Linke C, Tragiannidis A, Ahlmann M, Fröhlich B, Wältermann M, Burkhardt B, Rossig C, Groll AH.

Mycoses. 2019 Oct;62(10):954-960. doi: 10.1111/myc.12968. Epub 2019 Aug 18.

PMID:
31332851
17.

A Protochlorophyllide (Pchlide) a Oxygenase for Plant Viability.

Reinbothe S, Bartsch S, Rossig C, Davis MY, Yuan S, Reinbothe C, Gray J.

Front Plant Sci. 2019 May 15;10:593. doi: 10.3389/fpls.2019.00593. eCollection 2019.

18.

Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation.

Zöllner SK, Herbrüggen H, Kolve H, Mihailovic N, Schubert F, Reicherts C, Rössig C, Groll AH.

Transpl Infect Dis. 2019 Oct;21(5):e13089. doi: 10.1111/tid.13089. Epub 2019 Aug 13.

PMID:
30972869
19.

Requirement for YAP1 signaling in myxoid liposarcoma.

Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S.

EMBO Mol Med. 2019 May;11(5). pii: e9889. doi: 10.15252/emmm.201809889.

20.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.

PMID:
30879952
21.

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):1061-1062. doi: 10.1038/s41375-019-0426-8.

PMID:
30842605
22.

SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.

Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grünewald I, Huss S, Eßeling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schöffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W.

Clin Cancer Res. 2019 Jun 15;25(12):3718-3731. doi: 10.1158/1078-0432.CCR-17-3553. Epub 2019 Feb 27.

PMID:
30814111
23.

Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.

Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner S, Simmet T, Becker J, Åman P, Wardelmann E, Huss S, Hartmann W.

Mol Cancer Ther. 2019 Apr;18(4):834-844. doi: 10.1158/1535-7163.MCT-18-0763. Epub 2019 Feb 20.

PMID:
30787173
24.

Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation.

Rauwolf K, Herbrüggen H, Zöllner S, Thorer H, Makarova O, Kaiser T, Pettke A, Rossig C, Burkhardt B, Groll AH.

J Viral Hepat. 2019 Apr;26(4):454-458. doi: 10.1111/jvh.13046. Epub 2018 Dec 28.

PMID:
30516856
25.

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.

Rossig C, Kailayangiri S, Jamitzky S, Altvater B.

Front Oncol. 2018 Nov 12;8:513. doi: 10.3389/fonc.2018.00513. eCollection 2018. Review.

26.

Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C.

Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14.

PMID:
30426671
27.

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28. Erratum in: Leukemia. 2019 Mar 7;:.

28.

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.

Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M.

Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9.

29.

Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL - results of the ALL-SCT 2003 trial.

Kuhlen M, Bader P, Sauer M, Albert MH, Gruhn B, Güngör T, Kropshofer G, Lang P, Lawitschka A, Metzler M, Pentek F, Rossig C, Schlegel PG, Schrappe M, Schrum J, Schulz A, Schwinger W, von Stackelberg A, Strahm B, Suttorp M, Luettichau IT, Wößmann W, Borkhardt A, Meisel R, Poetschger U, Glogova E, Peters C.

Br J Haematol. 2018 Oct;183(1):104-109. doi: 10.1111/bjh.15511. Epub 2018 Jul 20.

PMID:
30028016
30.

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.

van Eijkelenburg NKA, Rasche M, Ghazaly E, Dworzak MN, Klingebiel T, Rossig C, Leverger G, Stary J, De Bont ESJM, Chitu DA, Bertrand Y, Brethon B, Strahm B, van der Sluis IM, Kaspers GJL, Reinhardt D, Zwaan CM.

Haematologica. 2018 Sep;103(9):1484-1492. doi: 10.3324/haematol.2017.187153. Epub 2018 May 17.

31.

An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia.

Kaspers GJL, Niewerth D, Wilhelm BAJ, Scholte-van Houtem P, Lopez-Yurda M, Berkhof J, Cloos J, de Haas V, Mathôt RA, Attarbaschi A, Baruchel A, de Bont ES, Fagioli F, Rössig C, Klingebiel T, De Moerloose B, Nelken B, Palumbo G, Reinhardt D, Rohrlich PS, Simon P, von Stackelberg A, Zwaan CM.

Br J Haematol. 2018 May;181(4):523-527. doi: 10.1111/bjh.15233. Epub 2018 Apr 20.

PMID:
29676440
32.

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.

Spurny C, Kailayangiri S, Altvater B, Jamitzky S, Hartmann W, Wardelmann E, Ranft A, Dirksen U, Amler S, Hardes J, Fluegge M, Meltzer J, Farwick N, Greune L, Rossig C.

Oncotarget. 2017 Dec 22;9(5):6536-6549. doi: 10.18632/oncotarget.23815. eCollection 2018 Jan 19.

33.

Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.

Merker M, Meister MT, Rettinger E, Jarisch A, Soerensen J, Willasch A, Huenecke S, Cappel C, Bremm M, Salzmann-Manrique E, Krenn T, Rossig C, Kremens B, Koscielniak E, Klingebiel T, Bader P.

Bone Marrow Transplant. 2018 Jul;53(7):891-894. doi: 10.1038/s41409-018-0088-6. Epub 2018 Jan 24. No abstract available.

PMID:
29367709
34.

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Koristka S, Kegler A, Jureczek J, Hoffmann A, Ehninger A, Cartellieri M, Albert S, Rossig C, Ehninger G, Pietzsch J, Steinbach J, Bachmann M.

Oncotarget. 2017 Sep 18;8(65):108584-108603. doi: 10.18632/oncotarget.21017. eCollection 2017 Dec 12.

35.

CAR T cell immunotherapy in hematology and beyond.

Rossig C.

Clin Immunol. 2018 Jan;186:54-58. doi: 10.1016/j.clim.2017.09.016. Epub 2017 Sep 18.

PMID:
28923441
36.

Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.

Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26719. Epub 2017 Sep 4.

PMID:
28868758
37.

Successful Extracorporeal Life Support in a Pediatric Hematopoietic Stem Cell Transplant Recipient With Periengraftment Respiratory Failure.

Potratz J, Ahlmann M, Rössig C, Omran H, Masjosthusmann K.

J Pediatr Hematol Oncol. 2018 May;40(4):e256-e259. doi: 10.1097/MPH.0000000000000929.

PMID:
28816799
38.

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.

Kuhlen M, Bleckmann K, Möricke A, Schrappe M, Vieth S, Escherich G, Bronsema A, Vonalt A, Queudeville M, Zwaan CM, Ebinger M, Debatin KM, Klingebiel T, Koscielniak E, Rossig C, Burkhardt B, Kolb R, Eckert C, Borkhardt A, von Stackelberg A, Chen-Santel C.

Br J Haematol. 2017 Oct;179(2):272-283. doi: 10.1111/bjh.14877. Epub 2017 Aug 2.

PMID:
28771662
39.

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.

Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, Fröhling S, Hafner S, Simmet T, Åman P, Wardelmann E, Huss S, Hartmann W.

Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. doi: 10.1158/1078-0432.CCR-17-0130. Epub 2017 Jun 21.

40.

HP30-2, a mitochondrial PRAT protein for import of signal sequence-less precursor proteins in Arabidopsis thaliana.

Rossig C, Gray J, Valdes O, Rustgi S, von Wettstein D, Reinbothe C, Reinbothe S.

J Integr Plant Biol. 2017 Aug;59(8):535-551. doi: 10.1111/jipb.12555. Epub 2017 Jun 30.

PMID:
28544763
41.

Control of Multidrug-Resistant Pseudomonas aeruginosa in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems.

Kossow A, Kampmeier S, Willems S, Berdel WE, Groll AH, Burkhardt B, Rossig C, Groth C, Idelevich EA, Kipp F, Mellmann A, Stelljes M.

Clin Infect Dis. 2017 Sep 15;65(6):935-942. doi: 10.1093/cid/cix465. Erratum in: Clin Infect Dis. 2019 Jan 18;68(3):534. Burckhardt, Birgit [corrected to Burkhardt, Birgit].

PMID:
28520856
42.

Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma.

Ranft A, Seidel C, Hoffmann C, Paulussen M, Warby AC, van den Berg H, Ladenstein R, Rossig C, Dirksen U, Rosenbaum D, Juergens H.

J Clin Oncol. 2017 May 20;35(15):1704-1712. doi: 10.1200/JCO.2016.70.6226. Epub 2017 Mar 29.

PMID:
28355116
43.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C.

Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017.

44.

Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.

Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM.

Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9.

45.

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.

PMID:
28126984
46.

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.

Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23.

PMID:
28111878
47.

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.

Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28. No abstract available.

PMID:
27892950
48.

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity.

Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S.

Sarcoma. 2016;2016:7461783. Epub 2016 Oct 24.

49.

Rapid Diagnosis of an AT/RT by the Detection of a Heterozygous SMARCB1 Germ Line Deletion in an Infant.

Kerl K, Oyen F, Giannikopoulou D, Rössig C, Rellensmann G, Sandkötter J, Brentrup A, Selzer G, Schneppenheim R, Frühwald MC.

Pediatr Blood Cancer. 2016 Aug;63(8):1451-3. doi: 10.1002/pbc.25996. Epub 2016 Apr 19.

PMID:
27092963
50.

Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, von Laer D, Scheckenbach K, Wagenmann M, Reinhardt D, Kramm CM, Rettie AE, Wiek C, Hanenberg H.

Gene Ther. 2016 Jul;23(7):615-26. doi: 10.1038/gt.2016.38. Epub 2016 May 19.

PMID:
27092941

Supplemental Content

Loading ...
Support Center